AVITA Medical, Inc. (RCEL) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RCEL currently has 30.5M outstanding shares. with significant dilution risk as 57.5M authorized shares could dilute existing holders by 188.3%. The company has diluted shareholders by 18.01% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 14, 2026 |
10-Q filing | 30.5M shares outstanding |
31M | 57M |
| Mar 31, 2026 |
S-3 filing: AVITA MEDICAL, INC. is filing an S-3 form to register common stock, preferred stock, warrants, and units for an aggregate initial offering price not to exceed $200,000,000. |
28M | 60M |
| Jan 13, 2026 |
8-K filing: AVITA Medical, Inc. entered into a Credit Agreement and Guaranty for a five-year senior secured credit facility, and will issue a warrant to purchase up to an initial 500,000 shares of common stock, with an additional 150,000 shares if the Additional Commitment Amount is incurred. |
28M | 4.5M |
| Nov 06, 2025 |
10-Q filing | 28.4M shares outstanding |
28M | 4.5M |
| Aug 07, 2025 |
8-K filing: AVITA Medical, Inc. agreed to a fifth amendment to the Credit Agreement with OrbiMed Advisors, LLC, issuing 400,000 shares of common stock to the Lenders as a condition of the amendment. |
26M | 6.7M |
| May 08, 2025 |
10-Q filing | 26.3M shares outstanding |
26M | 6.7M |
| Feb 13, 2025 |
10-K filing | 25.9M shares outstanding |
26M | 7.1M |
| Feb 13, 2025 |
8-K filing: AVITA Medical, Inc. entered into a fourth amendment to the Credit Agreement with affiliates of OrbiMed Advisors, LLC, modifying financial covenants and issuing warrants to purchase up to 145,180 shares of common stock at an exercise price of $0.01 per share. |
26M | 7M |
| Nov 07, 2024 |
10-Q filing | 26.0M shares outstanding |
26M | 7M |
| Aug 08, 2024 |
10-Q filing | 25.8M shares outstanding |
26M | 7.2M |
| May 13, 2024 |
10-Q filing | 25.6M shares outstanding |
26M | 7.3M |
| Feb 22, 2024 |
10-K filing | 25.3M shares outstanding |
25M | 7.6M |
| Nov 09, 2023 |
10-Q filing | 25.4M shares outstanding |
25M | 7.5M |
| Oct 18, 2023 |
8-K filing: AVITA Medical, Inc. entered into a Credit Agreement for a $90 million senior secured credit facility and issued a warrant to purchase up to 409,661 shares of common stock to an affiliate of OrbiMed. |
25M | 7.7M |
| Aug 10, 2023 |
10-Q filing | 25.2M shares outstanding |
25M | 7.7M |
| May 11, 2023 |
10-Q filing | 25.2M shares outstanding |
25M | 7.7M |
| Apr 14, 2023 |
S-3 filing: AVITA MEDICAL, INC. is offering common stock, preferred stock, warrants and units, with an aggregate initial offering price not to exceed $200,000,000. |
25M | 7.9M |
| Feb 23, 2023 |
10-K filing | 25.0M shares outstanding |
25M | 0 |
| Nov 10, 2022 |
10-Q filing | 25.0M shares outstanding |
25M | 0 |
| Aug 11, 2022 |
10-Q filing | 25.0M shares outstanding |
25M | 0 |
| May 12, 2022 |
10-Q filing | 24.9M shares outstanding |
25M | 0 |
| Nov 08, 2021 |
10-Q filing | 24.9M shares outstanding |
25M | 0 |
| Aug 26, 2021 |
10-K filing | 22.7M shares outstanding |
23M | 0 |
| May 13, 2021 |
10-Q filing | 24.8M shares outstanding |
25M | 0 |
| Feb 16, 2021 |
10-Q filing | 21.6M shares outstanding |
22M | 0 |
| Nov 10, 2020 |
10-Q filing | 21.5M shares outstanding |
22M | 0 |
| Oct 09, 2020 |
S-3 filing: AVITA Therapeutics, Inc. may offer and sell common stock, preferred stock, warrants, and units up to an aggregate initial offering price of $200,000,000. |
20M | 0 |
| Aug 27, 2020 |
10-K filing | 20.3M shares outstanding |
20M | 0 |